PT - JOURNAL ARTICLE AU - Neil P. Oxtoby AU - Cameron Shand AU - David M. Cash AU - Daniel C. Alexander AU - Frederik Barkhof AU - for the Alzheimer’s Disease Neuroimaging Initiative AU - the Alzheimer’s Disease Cooperative Study TI - Targeted screening for Alzheimer’s disease clinical trials using data-driven disease progression models AID - 10.1101/2021.01.29.21250773 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.29.21250773 4099 - http://medrxiv.org/content/early/2021/02/01/2021.01.29.21250773.short 4100 - http://medrxiv.org/content/early/2021/02/01/2021.01.29.21250773.full AB - Heterogeneity in Alzheimer’s disease progression contributes to the ongoing failure to demonstrate efficacy of putative disease-modifying therapeutics that have been trialled over the past two decades. Any treatment effect present in a subgroup of trial participants (responders) can be diluted by non-responders who ideally should have been screened out of the trial. How to identify (screen-in) the most likely potential responders is an important question that is still without an answer. Here we pilot a computational screening tool that leverages recent advances in data-driven disease progression modelling to improve stratification. This aims to increase the sensitivity to treatment effect by screening out non-responders, which will ultimately reduce the size, duration, and cost of a clinical trial. We demonstrate the concept of such a computational screening tool by retrospectively analysing a completed double-blind clinical trial of donepezil in people with amnestic mild cognitive impairment (clinicaltrials.gov: NCT00000173), identifying a data-driven subgroup having more severe cognitive impairment who showed clearer treatment response than observed for the full cohort.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNPO is a UKRI Future Leaders Fellow. NPO and CS both acknowledge funding from the UKRI Medical Research Council (MRC MR/S03546X/1). NPO, DCA, and FB acknowledge funding from the EuroPOND project: This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 666992; and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The funders had no role in the design nor conduct of this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCL Computer Science Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analysed in this study can be obtained from the respective data controllers: the Alzheimer's Disease Neuroimaging Initiative (ADNI: adni.loni.usc.edu) and Alzheimer's Disease Cooperative Study (ADCS: www.adcs.org). Supporting code for the analyses performed herein can be obtained by contacting the corresponding author. https://adni.loni.usc.edu https://www.adcs.org